AbCellera Biologics Inc. Common Shares
$12.63
-$0.10 (-0.79%)
$12.37Day Range$12.96
Key Statistics
Market Cap
$4.13B
Shares Outstanding
324.0M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 11, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$12.73
Day High
$12.96
Day Low
$12.37
Volume
5.44M
VWAP
$12.58
Prev Close
$12.73
Transactions
--
Acc. Volume
--
About AbCellera Biologics Inc. Common Shares
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
PHARMACEUTICAL PREPARATIONSSIC 2834562 employees150 W 4TH AVENUE, VANCOUVER, A1, V5Y 1G6(604) 559-9005IPO Dec 11, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001703057
- Composite FIGI
- BBG00LLW2MF2
- Share Class FIGI
- BBG00LLW2MH0
- Ticker Root
- ABCL
- SIC Code
- 2834
About AbCellera Biologics Inc. Common Shares (ABCL) Stock
AbCellera Biologics Inc. Common Shares (ABCL) closed the 2026-09-18 session at $12.63, down 0.79% versus the previous close (-0.10). The stock opened at $12.73 and traded between $12.37 and $12.96 during that session. Session trading volume was 5.4M shares. The volume-weighted average price (VWAP) is $12.58.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.
AbCellera Biologics Inc. Common Shares has a market capitalization of $4.13 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. ABCL is listed on the XNAS exchange. The company employs approximately 562 people. AbCellera Biologics Inc. Common Shares is headquartered in VANCOUVER, A1. The recorded listing date is 2020-12-11.
On this page you can find market ABCL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.